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Abstract
Objective: The use of antiretrovirals (ARV) during pregnancy has drastically reduced the rate of the human
immunodeficiency virus perinatal transmission (MTCT). As a consequence of widespread ARV use, transmission of drug
resistant strains from mothers to their babies is increasing. Ultra-sensitive PCR techniques have permitted the quantification
of minority viral populations, but little is known about the transmission of drug-resistant HIV-1 minority population in the
setting of MTCT.
Methodology/Principal Findings: We describe the case of a female child born to an HIV-infected mother, which had not
taken any ARV during the pregnancy. The child’s first genotype demonstrated a minor non-nucleoside reverse transcriptase
inhibitor (K101E), and during her treatment with reverse transcriptase and protease inhibitors full resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTI) emerged (G190A). Phenotypic/genotypic analysis of variant quasispecies
through yeast TyHRT assay was conducted to characterize minority resistant viral strains circulating in both mother and
child. Maximum likelihood and Bayesian MCMC phylogenetic analyses were performed with samples from the pair to assess
genetic relatedness among minor viral strains. The analysis showed that the child received a minor NNRTI resistant variant,
containing the mutation K101E that was present in less than 1% of the mother’s quasispecies. Phylogenetic analyses have
suggested common ancestry between the mother’s virus strain carrying K101E with the viral sequences from the child.
Conclusion: This is the first documentation of MTCT of a minority resistant strain of HIV-1. The transmission of minor
resistant variants carries the threat of emergence of multi-drug primary mutations without identified specific selective
pressures.
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Introduction
The use of antiretrovirals (ARV), particularly the combination
therapy known as highly active antiretroviral therapy (HAART)
during pregnancy, has substantially decreased mother-to-child
transmission (MTCT). In addition to AZT prophylaxis during
delivery and to the newborn, C-section when viral suppression is
not achieved and avoidance of breastfeeding has reduced the rate
of MTCT to less than 2% [1]. As a consequence of ARV selective
pressure and widespread use, transmission of resistance strains
from mothers to their babies is increasing [2].
Vertical transmission of HIV-1 variants resistant to reverse
transcriptase inhibitors has been reported and some studies suggest
that resistant mutations are selectively transmitted [3–5]. More
recently, however, no vertical transmission of NNRTI and PI
major mutations has been observed, even when representing the
predominant maternal variant [5]. Studies using single-dose
nevirapine to MTCT prevention suggest that transmission of
NNRTI-resistant strains is a rare event, if it occurs at all [6–7].
Transmission of major NNRTI and PI mutations has been rarely
reported in infants born to mothers who acquired primary
resistance mutations by heterosexual transmission or during the
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can take years to fade away even when the population transmitted
is a mixture of wild-type and drug-resistant virus [10].
Little is known about the transmission of drug-resistant HIV-1
minority population in the setting of MTCT. We report here a
possible transmission of a minor variant carrying an NNRTI
resistance mutation from an ARV-naı ¨ve mother to a child and
subsequent emergence of this variant as a dominant population
during an NNRTI non-based ARV treatment.
Methods
Case description
P50 is a female child born on May 1, 1999 and diagnosed with
HIV on January 29, 2002. She was the index case of HIV-1 in the
family. Her parents had not taken any ARV at the time of the
child’s diagnosis and her mother did not take any ARV during the
pregnancy. The child was not breastfed. Her first CD4
+ T-cell
count was 308/mL (14%) and her viral load (VL) was 390,000
copies/ml. She was started on zidovudine and didanosine in
August, 2002. One month after initiation of treatment her CD4
+
counts rose to 28% and her VL was 1,700 HIV-RNA copies/ml,
but DDI was changed for lamivudine and nelfinavir due to
intolerance. She experienced immunological improvement during
HAART although her VL was never undetectable. Her baseline
genotyping test before ARV therapy showed the K101E RT
mutation. A second genotyping performed one month after
HAART showed K101E, G190A, and T215F. Another test
performed 13 months after HAART initiation revealed the
persistence of G190A and K101E and the accumulation of
various NRTI mutations (Table 1).
In order to evaluate whether the NNRTI primary mutation,
G190A, was already presented in the child’s quasispecies before
the introduction of ARV, we analyzed the child’s sample before
the initiation of therapy. One sample of the mother (M50),
collected on October, 2005, while she was still ARV-naı ¨ve was also
analyzed for minor variants. Written informed consent was
obtained from the mother prior to inclusion of both mother and
child in the study.
Phenotypic/Genotypic analysis of quasispecies variants
through yeast TyHRT assay
Patient-derived HIV-1 RT domain DNA encompassing
codons 37–250 was isolated through nested PCR from in-
fected PBMC genomic DNA using primers Dp10 (59CAACT-
CCCTCTCAGAAGCAGGAGCCG39) and PolM4 (59TATG-
TAGATGGGGC AGCTAACAG39) for the first round, and
primers Dp16 (59CCTCAAATCACTCTTTGG CAAC39) and
RT-20 (59GAAGAAGCAGAGCTAGAACTGGCAG39) for the
second round. RT sequences were incorporated into TyHRT
elements by in vivo homologous recombination following transfor-
mation into Saccharomyces cervisiae. HIV-1 RT assays using TyHRT
elements in yeast [11] and the construction of RT domain libraries
[12] were carried out as described previously. Clones were assayed
in the absence and presence of efavirenz and nevirapine (obtained
from the NIH AIDS Research and Reference Reagent Program)
to monitor RT activity and NNRTI susceptibility. Nevirapine-
and efavirenz-resistant RTs with increased activity in the presence
of inhibitor were characterized further.
HIV-1 RT domains of interest were isolated and sequenced as
described previously [13]. RTs were amplified using primers A-35
(59GAACCTCCGAGATCGAAGA39) and I1097 (59GCACTG-
CCTCTGTTAATTGT39) and sequenced with internal primers
44F (59GGATGGATGGCCCAAAAGT39) and J801 (59ATCCC-
TGGGTAAATCTGACT39).
Phylogenetic analyses
Phylogenetic analysis was performed using both maximum
likelihood (ML) and Bayesian inference algorithms. To establish
the epidemiological linkage of the M50-P50 mother-child pair,
additional subtype B control sequences were obtained from the
same geographical region (14 sequences form HIV infected
children in Rio de Janeiro) and using BLAST similarity searches
in GenBank (49 sequences). Analyses for the M50-P50 sequences
were performed with and without codon 101 to avoid the effect of
convergent evolution of the K101E substitution. ML trees were
inferred using PhyML [14], employing a General Time Reversible
model with discrete gamma-distributed rate variation among sites
(GTR-c; 4 categories). Bootstrap analysis was performed using 500
replicates. Bayesian phylogenetic analysis was performed using
MrBayes with the same model settings as the ML analyses. Two
independent Markov Chain Monte Carlo (MCMC) runs were
carried out, each consisting of 4 chains and a default heating
scheme. ML trees and MCMC consensus trees were visualized in
FigTree (http://tree.bio.ed.ac.uk/ software/figtree/).
Ethics Statement
Results
HIV-1 Quasispecies analyses
A total of 680 isolates with active RT from the child (referred as
P50) and 2,931 sequences from the mother (M50) were tested.
With respect to resistance phenotype, P50 showed 46 isolates
associated with resistance to nevirapine and twenty resistant to
efavirenz. Among M50 sequences, 22 were associated with
resistance to nevirapine and 16 to efavirenz. None of 344 NNRTI
Table 1. Evolution of resistance mutation profile of child P50, detected by standard genotyping.
Age Treatment History Standard Genotyping*
2 yrs 8 months HIV diagnosis
3 yrs No ARV K101E
3 yrs 3 months AZT+DDI
3 years 4 months AZT+3TC+NFV
3 yrs 5 months AZT+3TC+NFV K101E, G190A, T215F
4 years 5 months AZT+3TC+NFV M41L, D67N, T69N, K70R, K101E, M184V, G190A, T215F , K219E
*Only major drug resistance mutations are listed.
ARV=antiretrovirals, AZT=zidovudine, DDI=didanosine, 3TC=lamivudine, NFV=nelfinavir.
doi:10.1371/journal.pone.0004806.t001
NNRTI Mutations during HAART
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mutation. Successful sequencing of resistant clones was obtained
for 14 NNRTI-resistant variants from P50 and 30 from M50.
Among P50 sequences the mutations A98S, K101E, I135T and
E138A were observed in all isolates. In seven of these sequences
the G190A mutation was present. Other polymorphisms (L100I,
L100S, V106A) were observed in individual sequences but were
not associated with G190A mutation. M50 sequences also showed
mutations A98S, I135T and E138A. NNRTI-resistant V106A and
K103N variants were seen in two sequences, Y181C and Y188C
in two sequences, and Y188H in five sequences. K101E was found
in one sequence.
Phylogenetic relatedness between M50 and P50 HIV-1
sequences
Phylogenetic analysis of M50-P50 clonal sequences and
additional controls clearly showed the mother-to-child transmis-
sion linkage with high bootstrap support. Only sequences larger
than 780 bp were included for clarity of phylogenetic signal
(Figure 1). A well-supported cluster was inferred for both the
transmission chain and the individual patient sequences. The
phylogenetic relationships between the mother and the child
clones are presented in more detail in Figure 2. The K101E-
containing variant from the mother (M50_13B_K101E) showed
phylogenetic evidence of common ancestry with the child cluster,
as seen by the net formed by both clusters (Figure 2A). Although
exclusion of codon 101 from the analysis failed to show such
linkage, M50_13B_K101E still remained at the base of the mother
cluster, as one of the sequences from the mother most similar to
the child cluster (Figure 2B).
The Bayesian MCMC analysis revealed that the cluster from
the mother harboring sequence M50_13B_K101E was indeed
more closely-related to the child cluster (Figure 3). Taken together,
all phylogenetic evidences suggest that M50_13B_K101E, the only
viral sequence from the mother carrying K101E, share common
ancestry with viruses circulating in P50.
Discussion
We have reported here the description of MTCT of a minor
HIV-1 variant carrying the NNRTI mutation K101E. The child
Figure 1. Maximum likelihood tree with bootstrap support values for the M50-P50 transmission chain including control sequences.
Only bootstrap support values over 70% are shown. The Bayesian phylogenetic inference produced very similar results.
doi:10.1371/journal.pone.0004806.g001
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formation of a net (pointed by the arrow) in A depicts genetic relatedness between sequence M50_13B_K101E and the child viral sequence cluster.
M50_13B_K101E is boxed in both panels.
doi:10.1371/journal.pone.0004806.g002
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predominant species also carrying the G190A mutation, which
confers resistance to all NNRTI, albeit in the absence of NNRTI
selective pressure.
K101E mutation can cause resistance to nevirapine and a low
level resistance to efavirenz and etravirine [15–16]. The fitness of
variants containing solely the K101E mutation remains to be
determined but its persistence in the child along all her follow-up
and our phylogenetic evidences suggest that this variant was the
founder species transmitted to the child even though it was present
in less than 0.3% of the mother’s viral quasispecies.
Our standard genotyping showed that K101E was already
present in the first sample of the child (before treatment) but only
the minority of the virus population had the NNRTI major
mutation G190A. The standard genotyping was able to detect
G190A mutation only one month after start of ARV, when the
T215F mutation was already present (Table 1). The fact that
G190A was not observed in the mother’s genotyping may suggest
that it could have emerged de novo in the backbone containing
K101E during evolution of the child quasispecies. G190A is
known to impact only slightly in viral fitness [17], and could have
remained in the quasispecies until selected as a major variant by
the emergence of T215F and NRTI selective pressure. Alterna-
tively, it may have faded away over time from the mother’s virus
population, as her first sample was collected 4 years after her HIV
diagnosis. The mother presented some minor HIV variants
carrying NNRTI resistant mutations, suggesting that she was
infected with a NNRTI primary resistant virus. Finally, G190A
could be present in a very small frequency in the mother’s viral
quasispecies, below the detection limit of the assays. Wang et al.
[18] have shown that certain NRTI mutations, including T215Y,
can increase the fitness of K101E+G190S variants. We speculate
that T215F has emerged in those viral species already carrying
both NNRTI mutations, and the selective pressure of NRTI in the
child propitiated the emergence of G190A-containing strains as
major variants.
Although the horizontal transmission of HIV minority resistant
strains [19] and the vertical transmission of resistant strains [20]
have been both previously reported, this is the first documentation,
to the best of our knowledge, of MTCT of minority resistant
strains of HIV-1.
Our report highlights the importance of transmission of resistant
minority strains, as it carries the threat of emergence of multi-drug
resistance primary mutations without specific selective pressures.
Pediatricians who provide care to HIV-infected children should be
aware of this possibility, especially when dealing with children who
acquired HIV by vertical transmission and whose mothers were
treated with ARV during pregnancy. The use of ultrasensitive
genotyping technologies for the detection of drug resistance in
MTCT cases may not be feasible for most developing countries. In
this setting, the early use of standard genotyping tests in children
with virologic failure during treatment can promote the detection
of unsuspected resistant mutations and optimization of their future
ARV regimens.
Author Contributions
Conceived and designed the experiments: ESM MAS. Performed the
experiments: AOA DVN. Analyzed the data: ESM AOA DVN PL MAS.
Contributed reagents/materials/analysis tools: ESM DVN PL SCMC
RHO MAS. Wrote the paper: ESM MAS.
Figure 3. Majority-rule consensus tree of the Bayesian MCMC analyses. Only posterior probablities .0.75 are shown. The maximum
likelihood tree showed a very similar clustering. The arrow indicates the closer relatedness between the mother sequence cluster harboring
M50_13B_K101E (boxed) and the child cluster.
doi:10.1371/journal.pone.0004806.g003
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